

**Priority question for written answer P-002901/2025
to the Commission**

Rule 144

**Jaroslava Pokorná Jermanová (PfE), Jaroslav Bžoch (PfE), Nikola Bartůšek (PfE),
Virginie Joron (PfE), Tomáš Kubín (PfE), Ondřej Knotek (PfE), Kateřina Konečná
(NI), Klara Dostalova (PfE), Geadis Geadí (ECR), Julien Leonardelli (PfE), Margarita
de la Pisa Carrión (PfE)**

Subject: Abolition of paper package leaflets for medicinal products

Our urgent written question concerns the proposal currently under discussion on the abolition of paper package leaflets for medicinal products within the territory of the European Union. This step, which is part of a broader digitalisation strategy in the field of healthcare and pharmaceuticals, raises numerous questions and concerns among both medical professionals and the public.

1. How does the Commission intend to ensure that information about medicines remains easily accessible to all population groups including senior citizens, people without internet access or those who are not digitally literate?
2. Has the Commission considered the consequences of this measure in terms of patient safety, especially regarding the risk of incorrect use of medicines in the absence of easily accessible instructions?
3. Has the Commission considered the potential risk of disruption to the availability of medicines that could result from abolishing the requirement to repackage medicines in national languages – potentially encouraging increased exports to higher-priced countries – and thereby threatening access to medicines in Member States with lower prices?

Supporters¹

Submitted: 15.7.2025

¹ This question is supported by Members other than the authors: Filip Turek (PfE), Pál Szekeres (PfE), Viktória Ferenc (PfE), Ruth Firmenich (NI), Tomasz Froelich (ESN), Ondřej Krutílek (ECR)